[Skip to Content]
[Skip to Content Landing]
Views 282
Citations 0
Research Letter
November 21, 2018

Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and DexamethasoneFive-Year Follow-up of a Phase 2 Clinical Trial

Author Affiliations
  • 1Myeloma Program, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
  • 2Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City
  • 3Department of Pharmacokinetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
JAMA Oncol. Published online November 21, 2018. doi:10.1001/jamaoncol.2018.5457

State-of-the art treatment of multiple myeloma (MM) involves induction with triplet-based regimens using combinations of immunomodulatory drugs and proteasome inhibitors, which have shown improved progression-free survival and overall survival compared with doublet regimens in the newly diagnosed (ND) and relapsed and refractory (RR) setting.1-3 Carfilzomib is a selective proteasome inhibitor approved by the US Food and Drug Administration for use in the carfilzomib, lenalidomide, and dexamethasone (KRd) regimen for the treatment of RRMM.3,4 We previously reported early data on this phase 2 study of 45 patients with NDMM.5 Herein, we expand on our initial results and present the long-term durability of minimal residual disease–negative complete remissions (MRD-negative CRs) and time to progression, the last characterized by depth of response, age, and cytogenetic risk profile.

×